Chong Kun Dang Pharmaceutical
Chong Kun Dang Pharmaceutical Corp. engages in the manufacturing, marketing, and sales of medicines in South Korea and internationally. The company provides prescription drugs for anti-hypertension, anti-hyperlipidemia, anti-diabetics, and immunosuppressants; over-the-counter medicine comprising headache remedies, dewormers, digestive aids, and vitamins; probiotics and Omega-3 supplements; and he… Read more
Chong Kun Dang Pharmaceutical (185750) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.023x
Based on the latest financial reports, Chong Kun Dang Pharmaceutical (185750) has a cash flow conversion efficiency ratio of 0.023x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩21.45 Billion) by net assets (₩945.54 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Chong Kun Dang Pharmaceutical - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Chong Kun Dang Pharmaceutical's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Chong Kun Dang Pharmaceutical Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Chong Kun Dang Pharmaceutical ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bikaji Foods International Limited
NSE:BIKAJI
|
0.020x |
|
Zhejiang Baoxiniao Garment Co Ltd
SHE:002154
|
0.001x |
|
Shenzhen MYS Environmental Protection & Technology Co Ltd
SHE:002303
|
0.003x |
|
Accel Entertainment Inc
NYSE:ACEL
|
0.114x |
|
Jiayuan Science and Technology Co.Ltd.
SHE:301117
|
N/A |
|
Hubei Kailong Chemical Group Co Ltd
SHE:002783
|
0.000x |
|
Laan & Spar Bank AS
CO:LASP
|
-0.418x |
|
Banco de Valores SA
BA:VALO
|
1.856x |
Annual Cash Flow Conversion Efficiency for Chong Kun Dang Pharmaceutical (2016–2024)
The table below shows the annual cash flow conversion efficiency of Chong Kun Dang Pharmaceutical from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩896.38 Billion | ₩64.29 Billion | 0.072x | -81.61% |
| 2023-12-31 | ₩815.64 Billion | ₩318.16 Billion | 0.390x | +257.79% |
| 2022-12-31 | ₩621.29 Billion | ₩67.73 Billion | 0.109x | +378.04% |
| 2021-12-31 | ₩565.81 Billion | ₩12.90 Billion | 0.023x | -87.94% |
| 2020-12-31 | ₩551.59 Billion | ₩104.32 Billion | 0.189x | +16.22% |
| 2019-12-31 | ₩474.95 Billion | ₩77.29 Billion | 0.163x | +64.50% |
| 2018-12-31 | ₩430.90 Billion | ₩42.63 Billion | 0.099x | -51.15% |
| 2017-12-31 | ₩403.29 Billion | ₩81.67 Billion | 0.203x | +24.15% |
| 2016-12-31 | ₩354.25 Billion | ₩57.79 Billion | 0.163x | -- |